Clinical trial
Single Dose and 34-Day Tolerance Study of INGAP Peptide in Insulin Deficient…
NCT00034255 · GMP Endotherapeutics, Industry · Completed
Key facts
| NCT number | NCT00034255 |
|---|---|
| Title | Single Dose and 34-Day Tolerance Study of INGAP Peptide in Insulin Deficient Patients |
| Official title | Single Dose and 34-Day Tolerance Study of INGAP Peptide in Insulin Deficient Patients |
| Lead sponsor | GMP Endotherapeutics, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Type 1, Type 2 |
| Intervention type | Drug |
| Interventions | INGAP Peptide |
| Enrollment | 62 |
| Start date | Dec 1, 2001 |
| First posted | Apr 25, 2002 |
| Last update posted | Jun 24, 2005 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: